lctgmeetingsummary20251008
Differences
This shows you the differences between two versions of the page.
Next revision | Previous revision | ||
lctgmeetingsummary20251008 [2025.10.09 10:49] – created Steve Isenberg | lctgmeetingsummary20251008 [2025.10.09 11:08] (current) – Steve Isenberg | ||
---|---|---|---|
Line 7: | Line 7: | ||
====Quick recap==== | ====Quick recap==== | ||
+ | |||
+ | Susan Liebman shared personal stories about family members who died from dilated cardiomyopathy to highlight the importance of genetic testing and screening for heart conditions. She discussed the complexities of genetic mutations, testing methods, and the need for universal screening, while addressing common myths and challenges about genetic testing. Susan explored advancements in genetic cures and testing options, emphasizing the importance of early detection and treatment, and shared information about her book and resources for genetic testing. | ||
+ | |||
+ | ====Summary==== | ||
+ | |||
+ | ===Genetic DCM: A Family Tragedy=== | ||
+ | Susan shared personal stories about family members who died from dilated cardiomyopathy (DCM), a heart condition. She described how her sister' | ||
+ | |||
+ | ===Genetic Testing for Heart Health=== | ||
+ | Susan discussed the importance of genetic testing and screening to prevent heart disease tragedies, highlighting that despite clear guidelines, adoption by cardiologists remains low. She addressed myths about genetic testing, such as beliefs of its high cost and complexity, emphasizing that it is now affordable and relatively straightforward. Susan also explained that genetic heart conditions can affect people of all ages and that learning about mutations can lead to early interventions that save lives. She concluded by describing the different genetic bases for heart disease and the prevalence of cardiomyopathies caused by genetic mutations, emphasizing the need for proactive treatment to prevent sudden death. | ||
+ | |||
+ | ===Genetic Mutations and Clinical Implications=== | ||
+ | Susan explained how monogenic mutations can cause disease by disrupting protein function, distinguishing between recessive and dominant mutations. She emphasized that genetic testing can help detect disease early but requires follow-up clinical care, as not all pathogenic mutations guarantee illness. Susan discussed the challenges of classifying variants of unknown significance and highlighted the importance of actionable genes, which are genes where mutations can lead to interventions or treatments. She also covered the use of preimplantation genetic testing for expectant parents and the need for increased clinical screenings for individuals with mutations in actionable genes. | ||
+ | |||
+ | ===Universal Genetic Screening Advocacy=== | ||
+ | Susan shared personal stories about genetic testing and family history to illustrate the complexities of penetrance and the importance of universal screening. She emphasized that having a genetic mutation does not guarantee you'll have the disease, but the mutation can be passed to future generations, | ||
+ | |||
+ | ===Advancements in Genetic Cures=== | ||
+ | Susan discussed the advancements in genetic cures, including CRISPR and a specific injection for spinal muscular atrophy. She explained how engineering feats like adding or amplifying genes can prevent or treat diseases caused by protein deficiencies. Susan highlighted the importance of genetic testing for early treatment and protection, mentioning the 84 actionable genes in a testing panel. She encouraged attendees to consider getting tested, offering resources like Picture Genetics and the Genetic Cardiomyopathy Awareness Consortium for affordable and free testing options. Susan also promoted ConnectMyVariant.org, | ||
+ | |||
+ | ===Genetic Testing and Family Health=== | ||
+ | Susan shared a trailer for her book, //The Dressmaker' | ||
+ | |||
+ | ===Genetic Testing: Opportunities and Challenges=== | ||
+ | Susan explained the limitations and potential of genetic testing, noting that current tests sequence a small portion of DNA and are not clinical, but can identify genes linked to diseases. She discussed the possibility of modifying genes with CRISPR and the importance of early detection and treatment. Susan also addressed the debate over sequencing all infants' | ||
+ | |||
+ | ===Genetic Testing Privacy Options Discussed=== | ||
+ | Susan discussed genetic testing options, noting that while academic sequencing groups can provide confidential results directly to individuals, | ||
+ | |||
+ | ===Genetic Testing and Analysis Challenges=== | ||
+ | Susan explained the differences between panel testing for specific genes and whole genome sequencing. She discussed the challenges of analyzing genetic data, including the complexity of polygenic conditions where multiple genes contribute to a disease. Susan emphasized that current genetic testing systems are not yet fully developed to provide comprehensive analysis of complex genetic conditions, and expressed concerns about the lack of transparency in some genetic testing practices. The group discussed the potential for AI and computer systems to improve genetic research and analysis in the future. |
lctgmeetingsummary20251008.1760032183.txt.gz · Last modified: by Steve Isenberg